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The Roll Back Malaria partnership – a consortium of
donor and malaria-endemic countries, researchers, pol-
icy-makers and private sector enterprises – has helped
change the global perspective on malaria. Today, malaria
is high on the development agenda, financial resources
for countries have increased, more and more success sto-
ries in countries are being documented and there is
renewed hope that the disease can be beaten. Today, there
is new momentum.
In September 2008, the member organizations of the Roll
Back Malaria Partnership unveiled the Global Malaria
Action Plan [1], which, if fully implemented, could save
4.2 million lives by 2015 ...and more beyond.
The Plan is the first single comprehensive blueprint for
global malaria control and elimination. It charts the way
forward to scale up malaria control in the short term, then
eliminate and, eventually, eradicate malaria in the future.
It is built on consensus between all partners and it is built
on strategies that work. The Plan promotes the use of
insecticide-treated nets (particularly those lasting between
three to five years) indoor spraying with insecticides, pre-
ventive treatment for pregnant women and access to effec-
tive treatment – that is, artemisinin-based combination
therapy or ACT.
Global in scope, the Plan includes regional approaches,
which reach all endemic countries in the world, and it
focuses on all species of malaria parasite (Plasmodium fal-
ciparum, Plasmodium malariae, Plasmodium ovale and Plas-
modium vivax).
For the first time, all stakeholders fighting malaria have at
their disposal a single plan agreed by all. But this plan is
also a bridge – between good intentions and real action,
and between commitments and the delivery and use of
interventions in families and villages suffering needlessly
from malaria.
The Global Malaria Action Plan tells us exactly, region-
by-region and year-by-year, what is required and what it
will cost.
Despite the efficacy of today's tools, achieving near-term
goals of reducing incidence and reducing mortality, as
well as the longer-term goals of elimination and eradica-
tion, will require new and improved tools that are effec-
tive across a variety of settings and populations. Strategies
for scaling up, and sustaining control and elimination
cannot be discussed without acknowledging the crucial
role that research plays in enabling these strategies' suc-
cess. Lessons learned from the field will feed back into the
R&D process, thus informing new research directions. We
will also need to generate knowledge to inform policy
decisions and improve the use and effectiveness of current
and new interventions. The malaria research agenda car-
ries a price tag: USD 750–900 million a year over the next
decade for new tools alone. Yet, without this expense
malaria cannot be beaten.
If there ever was a golden age for malaria research and
innovation, it is now.
Research institutions, public private partnership and joint
ventures, have been at the forefront of recent research
advances against malaria including vaccine and drug
development, supporting local research capacity in Africa
and improving delivery of interventions.
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Such milestones in scientific and operational research are
setting the stage for increased investment in innovative
malaria initiatives. At the recent launch of the Global
Malaria Action Plan in New York on 25 Sept 2008, The
Bill and Melinda Gates Foundation pledged USD 168 mil-
lion to continued vaccine development and expanding
the vaccine R&D pipeline with projects ranging from
early-stage laboratory research to advanced clinical test-
ing.
Armed with the Plan's globally agreed research agenda,
partners and advocates can now bring more investment to
malaria research and foster further dialogue and innova-
tion. The Global Plan requires a long-term commitment:
continued funding is essential in both country implemen-
tation and R&D to prevent a re-emergence of malaria.
However, the investment is worthwhile.
Malaria control is cost effective, saving more lives per dol-
lar spent than interventions for most other diseases. R&D
investment today in new and improved interventions can
help countries eliminate malaria faster and reduce the
need for longer-term R&D costs.
I would like to congratulate the authors of this supple-
ment 'The Scientific Basis of Research for Global Malaria
Control' for their comprehensive examination of critical
areas that need to be tackled if we are to progress swiftly
towards malaria elimination and eventual eradication.
From vaccine development, integrated vector control,
treatment, confronting economic and financing issues to
climate change; these are the very real challenges of today
– but, with more investment in research – the accomplish-
ments of tomorrow.
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